| Identification | Back Directory | [Name]
apratastat | [CAS]
287405-51-0 | [Synonyms]
TMI 005
apratastat
TMI 005 - Apratastat
Apratastat >=98% (HPLC)
N-hydroxy-4-[[4-[(4-hydroxy-2-butynyl)oxy]phenyl]sulfonyl]-2,2-dimethyl-3-thiomorpholinecarboxamide
3-Thiomorpholinecarboxamide, N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-, (3S)- | [Molecular Formula]
C17H22N2O6S2 | [MDL Number]
MFCD13152357 | [MOL File]
287405-51-0.mol | [Molecular Weight]
414.5 |
| Chemical Properties | Back Directory | [density ]
1.390 | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 25 mg/ml; DMSO: 25 mg/ml; DMSO:PBS (pH 7.2) (1:40): 0.02 mg/ml; Ethanol: 10 mg/ml | [form ]
A crystalline solid | [pka]
9.25±0.23(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Treatment of rheumatoid
arthritis. | [Definition]
ChEBI: Apratastat is a sulfonamide. | [Brand name]
(Wyeth). | [Biological Activity]
Apratast at (TMI-005) is an orally activepotent and selective dual inhibitor of disintegrin metalloenzyme 17 (ADAM17/ TACE) and matrix metalloprotease (MMP). | [in vivo]
Apratastat (10 mg/kg, i.p., administered twice at 4 and 16 hours post-induction) alleviats lung inflammation induced by Poly(I
) (HY-119307) and SARS-CoV-2 RBD-S protein in C57BL/6 mice[3].
Apratastat (10 mg/kg, p.o., once daily for 14 days) exhibits anti-tumor and anti-angiogenic activity in the MC38 xenograft C57BL/6 mouse model[4]. | Animal Model: | Poly(I
) (HY-107202) and SARS-CoV-2 RBD-S protein-induced lung inflammation model in C57BL/6 mice[3] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.), administered twice at 4 and 16 hours post-surgery | | Result: | Significantly reduced neutrophil and macrophage numbers in lung tissue, improved lung tissue morphology. |
| Animal Model: | MC38 colorectal cancer cell xenograft model in C57BL/6 mice[4] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 14 days | | Result: | Significantly inhibited tumor growth, reduced tumor angiogenesis and lymphangiogenesis. |
| [IC 50]
MMP |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|